AVTX- Avalo Therapeutics, Inc.

Insider activity in AVTX over the last quarter tilts toward selling: insiders offloaded a net 101,317 shares worth roughly $2.0M.

Classified under Biotechnology (Health Care sector), AVTX's insider flows are most useful compared with peers in the same group.

Insider Ownership

Role	Insider	Shares	Value	30d
CEO	Neil Garry Arthur	190.3K	-	-
Other	Boyd Taylor	95.0K	-	-
Other	Doyle Mittie	51.8K	$1.04M	-
CFO	Sullivan Christopher Ryan	39.9K	$651.7K	-
Other	Riley Jennifer	37.0K	$725.6K	-

Buys and sells only

10 filings · page 2

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
May 28, 2026	Doyle Mittie	Chief Medical Officer	Sale+OE	679	$16.00	$10,864.00	-1.4%	-	-
May 15, 2026	Doyle Mittie	Chief Medical Officer	Sale+OE	3,000	$18.76	$56,280.00	-45.3%	-	-
May 7, 2026	Sullivan Christopher Ryan	Chief Financial Officer	Sale+OE	18,606	$24.12	$448,817.65	-97.8%	-	-
May 6, 2026	Varki Paul	Chief Legal Officer	Sale+OE	75,063	$20.17	$1,513,673.14	-95.4%	-16.3%	-
May 6, 2026	Chan Mitchell	Director	Sell	3,167	$22.88	$72,460.96	-50.0%	-16.3%	-
May 6, 2026	Sullivan Christopher Ryan	Chief Financial Officer	Sale+OE	47,000	$20.19	$948,721.90	-99.1%	-16.3%	-
May 6, 2026	Doyle Mittie	Chief Medical Officer	Sale+OE	108,234	$20.61	$2,230,366.60	-96.8%	-16.3%	-
Apr 30, 2026	Sullivan Christopher Ryan	Chief Financial Officer	Sell	16,915	$13.16	$222,589.49	-97.6%	-	-
Apr 6, 2026	Doyle Mittie	Chief Medical Officer	Sale+OE	3,970	$18.01	$71,508.43	-52.3%	-	-
Apr 2, 2026	Sullivan Christopher Ryan	Chief Financial Officer	Sell	15,959	$16.96	$270,593.02	-47.9%	-2.6%	-